Cargando…
Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer
PURPOSE: Data on management of locally recurrent pancreatic cancer (LRPC) after primary resection are limited. Recently, surprisingly high overall survival rates were reported after irradiation with carbon ions. Here, we report on our clinical experience using carbon ion radiotherapy as definitive t...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940823/ https://www.ncbi.nlm.nih.gov/pubmed/34351449 http://dx.doi.org/10.1007/s00066-021-01827-9 |
_version_ | 1784672981089255424 |
---|---|
author | Liermann, Jakob Ben-Josef, Edgar Syed, Mustafa Debus, Juergen Herfarth, Klaus Naumann, Patrick |
author_facet | Liermann, Jakob Ben-Josef, Edgar Syed, Mustafa Debus, Juergen Herfarth, Klaus Naumann, Patrick |
author_sort | Liermann, Jakob |
collection | PubMed |
description | PURPOSE: Data on management of locally recurrent pancreatic cancer (LRPC) after primary resection are limited. Recently, surprisingly high overall survival rates were reported after irradiation with carbon ions. Here, we report on our clinical experience using carbon ion radiotherapy as definitive treatment in LRPC at the Heidelberg Ion-Beam Therapy Center (HIT). METHODS: Between 2015 and 2019, we treated 13 patients with LRPC with carbon ions with a median total dose of 48 Gy (RBE) in 12 fractions using an active raster-scanning technique at a rotating gantry. No concomitant chemotherapy was administered. Overall survival, local control, and toxicity rates were evaluated 18 months after the last patient finished radiotherapy. RESULTS: With a median follow-up time of 9.5 months, one patient is still alive (8%). Median OS was 12.7 months. Ten patients (77%) developed distant metastases. Additionally, one local recurrence (8%) and two regional tumor recurrences (15%) were observed. The estimated 1‑year local control and locoregional control rates were 87.5% and 75%, respectively. During radiotherapy, we registered one gastrointestinal bleeding CTCAE grade III (8%) due to gastritis. The bleeding was sufficiently managed with conservative therapy. No further higher-grade acute or late toxicities were observed. CONCLUSION: We demonstrate high local control rates in a rare cohort of LRPC patients treated with carbon ion radiotherapy. The observed median overall survival rate was not improved compared to historical in-house data using photon radiotherapy. This is likely due to a high rate of distant tumor progression, highlighting the necessity of additional chemotherapy. |
format | Online Article Text |
id | pubmed-8940823 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-89408232022-04-07 Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer Liermann, Jakob Ben-Josef, Edgar Syed, Mustafa Debus, Juergen Herfarth, Klaus Naumann, Patrick Strahlenther Onkol Original Article PURPOSE: Data on management of locally recurrent pancreatic cancer (LRPC) after primary resection are limited. Recently, surprisingly high overall survival rates were reported after irradiation with carbon ions. Here, we report on our clinical experience using carbon ion radiotherapy as definitive treatment in LRPC at the Heidelberg Ion-Beam Therapy Center (HIT). METHODS: Between 2015 and 2019, we treated 13 patients with LRPC with carbon ions with a median total dose of 48 Gy (RBE) in 12 fractions using an active raster-scanning technique at a rotating gantry. No concomitant chemotherapy was administered. Overall survival, local control, and toxicity rates were evaluated 18 months after the last patient finished radiotherapy. RESULTS: With a median follow-up time of 9.5 months, one patient is still alive (8%). Median OS was 12.7 months. Ten patients (77%) developed distant metastases. Additionally, one local recurrence (8%) and two regional tumor recurrences (15%) were observed. The estimated 1‑year local control and locoregional control rates were 87.5% and 75%, respectively. During radiotherapy, we registered one gastrointestinal bleeding CTCAE grade III (8%) due to gastritis. The bleeding was sufficiently managed with conservative therapy. No further higher-grade acute or late toxicities were observed. CONCLUSION: We demonstrate high local control rates in a rare cohort of LRPC patients treated with carbon ion radiotherapy. The observed median overall survival rate was not improved compared to historical in-house data using photon radiotherapy. This is likely due to a high rate of distant tumor progression, highlighting the necessity of additional chemotherapy. Springer Berlin Heidelberg 2021-08-05 2022 /pmc/articles/PMC8940823/ /pubmed/34351449 http://dx.doi.org/10.1007/s00066-021-01827-9 Text en © The Author(s) 2021 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Article Liermann, Jakob Ben-Josef, Edgar Syed, Mustafa Debus, Juergen Herfarth, Klaus Naumann, Patrick Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer |
title | Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer |
title_full | Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer |
title_fullStr | Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer |
title_full_unstemmed | Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer |
title_short | Carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer |
title_sort | carbon ion radiotherapy as definitive treatment in locally recurrent pancreatic cancer |
topic | Original Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8940823/ https://www.ncbi.nlm.nih.gov/pubmed/34351449 http://dx.doi.org/10.1007/s00066-021-01827-9 |
work_keys_str_mv | AT liermannjakob carbonionradiotherapyasdefinitivetreatmentinlocallyrecurrentpancreaticcancer AT benjosefedgar carbonionradiotherapyasdefinitivetreatmentinlocallyrecurrentpancreaticcancer AT syedmustafa carbonionradiotherapyasdefinitivetreatmentinlocallyrecurrentpancreaticcancer AT debusjuergen carbonionradiotherapyasdefinitivetreatmentinlocallyrecurrentpancreaticcancer AT herfarthklaus carbonionradiotherapyasdefinitivetreatmentinlocallyrecurrentpancreaticcancer AT naumannpatrick carbonionradiotherapyasdefinitivetreatmentinlocallyrecurrentpancreaticcancer |